Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2022 / Apr / A Picture Paints a Thousand… New Therapies?
Pharma and Biopharma

A Picture Paints a Thousand… New Therapies?

How AI-enabled tools can democratize cell painting to speed up drug discovery and reduce failure rates

By James Strachan 04/22/2022 1 min read

Share

Cell painting is a high-content profiling technology that uses up to six fluorescent dyes to visualize specific cellular components at the single-cell level. The assay essentially “paints” images of various components of the cell, including the nucleus, mitochondria, endoplasmic reticulum, cytoskeleton, and more. After microscopic images are captured, image analysis software converts them to data by extracting various measures of cellular morphology, called features. The results allow researchers to understand the effects of perturbagens, such as chemical compounds or genes, on the behavior of cells, feeding drug discovery and the characterization of bioactive molecules. 

Here, we speak with Angeline Lim, Senior Scientist at Molecular Devices, and David Egan, co-founder and CEO at Core Life Analytics, about a collaboration focused on using AI to make cell painting faster and more efficient.

What are the current limitations of cell painting? 
 

Cell painting workflows often prove time- and labor-intensive – a full screen may take several days to complete and generate massive amounts of data. Next, researchers face the challenge of extracting meaningful information from the resulting data, which can be overwhelming – either demanding the expertise of a data scientist or – in a worst-case scenario – wasting valuable data simply because of the lack of tools. 

How can AI-enabled technologies help? 
 

Overcoming the aforementioned hurdles requires additional computational tools. In the past, only a team of statisticians, data scientists, and software developers was capable of analyzing cell painting data with any reasonable and timely success. Now, AI can quickly facilitate the analysis of large image datasets. In addition to machine learning-enabled software that handles data extraction from images, AI-enabled tools such as StratoMineR – a data analytics software from Core Life Analytics – can also help scientists iteratively mine data for information without the help of a data scientist.

Could you share more details about your collaboration?
 

At Molecular Devices, our customers are largely biologists in the life sciences field – not data scientists – who seek us out for guidance around analyzing large datasets coming from their cell painting assays performed with our high-content cellular imaging systems. The cloud-powered data analytics solution from Core Life Analytics, called StratoMineR, offers users a self-guided workflow that enables researchers to easily derive meaning from their high-content data.

Our collaboration provides more biologists with the AI-enabled tools that deliver advanced data mining and analysis – reducing the dependency on data science expertise. 

And how might this benefit drug discovery?  
 

The democratization of data science with AI-enabled analytic software enables data-driven decision making. It has enormous potential for speeding up the drug discovery process and reducing failure rates.

Figure 1. Cluster analysis. A) A dendrogram that represents hierarchical relationships is shown. Wells belonging to the same cluster (numbered) are represented by colored bars. P-values based on the distance score are shown for each well. Note that cluster 9 consists of only staurosporine treated cells, whereas cluster 10 consists of only etoposide treated cells. B) Examples of compound-treated cells belonging to some of the clusters are shown. Cluster 5 consists of tetrandrine- and chloroquine-treated cells. Note the increased number of ER punctae in both wells. Cluster 4 consists of rotenone- and paclitaxel-treated cells. Note the presence of blebbing in some of the cells belonging in these wells, suggesting cytotoxic effects.
Figure 2. Feature extraction in IN Carta software. A) An analysis protocol was created in the IN Carta software to segment the various cellular structures. Here, we used the built-in nuclei model to achieve robust segmentation of nuclei across all treatments. Other cellular features such as cytoplasm compartment, actin filament network, ER, and mitochondria were also segmented.

Angeline Lim supports scientific, technical, and applications initiatives for Molecular Devices’ portfolio of ImageXpress high-content imaging systems and David Egan co-developed Core Life Analytics’ StratoMineR platform with his co-founder Wienand Omta to help biologists independently analyze complex datasets.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.